We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CRISPR THERAPTC (CRSP - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
CRISPR THERAPTC is a member of our Medical group, which includes 764 different companies and currently sits at #10 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CRSP is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CRSP's full-year earnings has moved 8.35% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, CRSP has returned 121.98% so far this year. Meanwhile, stocks in the Medical group have lost about 2.08% on average. As we can see, CRISPR THERAPTC is performing better than its sector in the calendar year.
Looking more specifically, CRSP belongs to the Medical - Biomedical and Genetics industry, which includes 283 individual stocks and currently sits at #107 in the Zacks Industry Rank. On average, stocks in this group have lost 8.27% this year, meaning that CRSP is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CRSP. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CRISPR THERAPTC (CRSP - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
CRISPR THERAPTC is a member of our Medical group, which includes 764 different companies and currently sits at #10 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CRSP is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CRSP's full-year earnings has moved 8.35% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, CRSP has returned 121.98% so far this year. Meanwhile, stocks in the Medical group have lost about 2.08% on average. As we can see, CRISPR THERAPTC is performing better than its sector in the calendar year.
Looking more specifically, CRSP belongs to the Medical - Biomedical and Genetics industry, which includes 283 individual stocks and currently sits at #107 in the Zacks Industry Rank. On average, stocks in this group have lost 8.27% this year, meaning that CRSP is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CRSP. The stock will be looking to continue its solid performance.